Association between APOC1 polymorphism and Alzheimer's disease: a case-control study and meta-analysis
Qin Zhou1, Fan Zhao2, Ze-ping Lv3
1The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics, Ministry of Health, Beijing, China ; Department of Neurology, Jiangbin hospital, Guangxi Zhuang Autonomous Region, Nanning, China.
Plos One
|February 6, 2014
Summary
The APOC1 gene variant, particularly the insertion allele, may increase Alzheimer's disease (AD) risk, especially when combined with APOE ε4. This genetic risk factor was observed across diverse populations, excluding African Americans.
Area of Science:
- Genetics
- Neuroscience
- Epidemiology
Background:
- Conflicting results exist regarding the association between APOC1 gene polymorphisms and Alzheimer's disease (AD) susceptibility.
- The role of APOC1 variants as a genetic risk factor for AD across diverse populations remains unclear.
Purpose of the Study:
- To investigate the association between the APOC1 gene and Alzheimer's disease (AD) risk.
- To perform a meta-analysis of existing studies to clarify the genetic contribution of APOC1 to AD.
Main Methods:
- A case-control study was conducted with 79 AD patients and 156 controls.
- A meta-analysis was performed, pooling data from 2092 AD patients and 2685 controls from previously published studies.
Main Results:
- The initial case-control study found no association between APOC1 variation and AD.
- Meta-analysis revealed the APOC1 rs11568822 polymorphism is associated with increased AD risk in Caucasians, Asians, and Caribbean Hispanics, but not African Americans.
- APOE ε4 carriers with the APOC1 insertion allele showed higher prevalence in AD patients (OR=2.79, P<0.01).
Conclusions:
- The APOC1 insertion allele, in conjunction with APOE ε4, is a potential risk factor for Alzheimer's disease development.
- This combined genetic factor may contribute to AD etiology in specific ethnic groups.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
12.4K
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
20.2K
Related Concept Videos
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
03:03Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K
01:11Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K